Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 9Dermatologic 3Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Colorectal Neoplasms 8Melanoma 6Head and Neck Neoplasms 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Rectal Neoplasms 2Prostatic Neoplasms 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

pembrolizumab 43Nivolumab 29atezolizumab 11Specimen Handling 10Cyclophosphamide 10Bevacizumab 10Paclitaxel 9Magnetic Resonance Spectroscopy 9cabozantinib 7Ipilimumab 7Carboplatin 7fludarabine 6durvalumab 6avelumab 6Sunitinib 6Sorafenib 6Oxaliplatin 6Fluorouracil 6Docetaxel 6spartalizumab 5sargramostim 5Leucovorin 5Cisplatin 5Cetuximab 5aldesleukin 4Trastuzumab 4Radiosurgery 4Psychiatric Rehabilitation 4Irinotecan 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × cemiplimab × Gastrointestinal × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡